Peptide education
AOD-9604
Advanced Obesity Drug 9604
AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone, built to keep the fat-metabolism signal without the growth effects. The concept was strong enough to reach a roughly 500-person obesity trial, and that trial, OPTIONS, found no statistically significant weight-loss benefit over placebo. The program was discontinued, and the molecule got a second life in clinics and gray-market vials, sold for fat loss through routes, mostly subcutaneous, that FDA says have no human data at all.
AOD-9604 is a failed obesity drug: its largest human trial missed, and the program was discontinued. What is sold today, mostly subcutaneous vials and oral-dissolving products, runs on routes with no controlled human evidence behind them.
Overview
Quick answer
The formal human studies were oral or intravenous. Much of the current market talks about subcutaneous vials, troches, oral dissolving tablets, capsules, and combination products. FDA's 2024 review said it did not identify human data for the proposed subcutaneous or transdermal routes.
What is AOD-9604?
A cyclic fragment from the C-terminal region of human growth hormone, sequence YLRIVQCRSVEGSCGF, designed to isolate a fat-metabolism effect from full growth hormone. FDA, registry, and chemistry sources track it as Tyr-hGH177-191.
What do people use it for or talk about?
Fat loss, stubborn fat, body composition, and weight-management stacks. Clinic and gray-market material adds cartilage, muscle repair, and recovery, none of which has human support; the osteoarthritis signal is rabbit-only.
What routes, amounts, and durations have been reported?
The human studies were oral, 0.25 to 30 mg per day for 12 or 24 weeks, with a 7-day tolerability study at 9, 27, or 54 mg, plus early IV single-dose work at 25 to 400 mcg/kg. FDA's compounding review lists today's marketed forms, 600 mcg/mL vials, 1 mg capsules, 250 mcg ODTs, troches, and combination blends, which describe what sellers offer rather than what worked in trials.
Why do route and product form matter?
Because the entire human record is oral and IV. A subcutaneous vial, troche, cream, or med-spa blend is a different exposure with different stability, immune, and quality questions, and FDA identified no human data for the subcutaneous or transdermal routes.
Reported practice
Commonly reported protocol
Clinic and community fat-loss protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
FDA, GSRS, and ClinicalTrials.gov materials establish the identity and investigational history of AOD-9604/LAT-8881. That history is not the same as approval for weight loss.
The 12-week oral study produced a reported low-dose signal, but the larger OPTIONS study found no statistically significant weight-loss difference versus placebo at primary or secondary endpoints.
Current marketing often emphasizes subcutaneous vials, troches, ODTs, capsules, transdermal use, and combinations. FDA did not identify human data for the proposed subcutaneous or transdermal routes.
Cartilage and osteoarthritis interest comes from rabbit work and gray-market narratives, not from human repair studies.
FDA highlighted missing impurity, aggregate, microbial, endotoxin, and characterization data. Public COAs can show a submitted sample result, but they leave sterile injectable quality and correct vial content open.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| AOD-9604 is an established human fat-loss peptide. | The human clinical record is much thinner than that claim. A small 12-week oral study was reported as showing modest weight and waist changes, most visible around 1 mg/day, but the larger 24-week OPTIONS trial did not show a significant advantage over placebo. | Rodent studies reported reduced body-weight gain, fat-oxidation signals, and beta-3 adrenergic dependence. That biology made the obesity program plausible, but it did not translate into convincing human efficacy. | Clinic, vendor, and forum discussion still frames it as a fat-loss or body-composition peptide, often with injectable or oral-dissolving products that do not match the main human study routes. | Overstated. There was an early finding, but the larger human obesity trial was negative. |
| Injectable AOD-9604 has strong human obesity evidence. | FDA's 2024 review did not identify human data for the proposed subcutaneous route. The historical obesity studies were oral or IV. | Route changes exposure, stability, immune presentation, and product risk. A peptide with oral and IV study history may behave differently when sold as a compounded injectable vial. | Subcutaneous vials are common in today's clinic and gray-market discussion, including examples of 600 mcg/mL vials in FDA materials. | Current subcutaneous market use is not the same thing as the historical oral and IV studies. |
| AOD-9604 repairs cartilage, joints, or muscle in humans. | A published human cartilage-repair efficacy study was not found in the reviewed material. | The osteoarthritis evidence comes from rabbit model work. It can justify preclinical interest, but it cannot carry a human repair claim. | Company-era clarification materials and black-market discussion attached AOD-9604 to cartilage and muscle-repair narratives. | No cartilage, joint, muscle-repair, or recovery benefit in humans is documented in these sources. |
| AOD-9604 is safe because it is GRAS. | FDA staff said AOD-9604 was not currently on FDA's GRAS list and that the cited GRAS material appeared to be self-determined. GRAS language concerns food-ingredient safety status, not drug approval, route-specific pharmacology, or long-term therapeutic use. | Safety questions include immunogenicity, aggregates, route-specific exposure, animal bone and liver signals, and long-term use. | Vendor and clinic pages may use purity or food-safety language, but therapeutic risk still depends on route, exposure, impurities, and duration. | Misleading when used as a shortcut for therapeutic safety. |
| What can a COA tell you about an AOD-9604 vial? | This is a manufacturing question, not an efficacy result. FDA found major characterization gaps in nomination materials and public COAs. | Purity by HPLC or LCMS/MS does not by itself show correct identity, peptide-related impurities, aggregation profile, sterility, endotoxin control, fill amount, stability, reconstitution behavior, or shipping integrity. | Public COAs reported values such as 99.735% purity, 97.847% HPLC purity, and a research-product specification of at least 95% purity. Those numbers can be sample-specific and limited. | A COA can be one narrow data point. FDA-reviewed injectable quality also requires sterility, endotoxin, identity, fill, stability, and manufacturing controls. |
Bottom line
Main takeaway
AOD-9604 is not an approved weight-loss drug. It is a growth-hormone fragment with suggestive animal data, one modest early human signal, and a larger human trial that came back negative.
Route is the whole question here: oral and IV study regimens say nothing about subcutaneous vials, troches, ODTs, capsules, transdermal products, or med-spa combinations.
Start with FDA's 2024 compounding review, the OPTIONS failure record, the company-linked clinical safety summaries, the ClinicalTrials.gov LAT-8881 history, and the public COA examples. Together they explain both the science and the market around it.
Identity
What it is
AOD-9604 is the 177-191 region of human growth hormone, cyclized with a disulfide bridge and capped with an extra tyrosine. The design goal was a targeted metabolic drug: fat effects without growth hormone's endocrine baggage.
The development arc is the real story. Rodent studies showed fat-oxidation and body-weight signals; a roughly 300-person 12-week oral study reported a modest low-dose signal; then the larger OPTIONS trial found nothing over placebo, and the obesity program ended.
The market skipped the ending. Today's AOD-9604 discussion centers on injectable fat loss, med-spa products, oral dissolving tablets, and repair claims the old studies never tested, while a later LAT-8881 program quietly repurposed the molecule toward a pain hypothesis.
How people talk about it online
Clinic and vendor pages sell AOD-9604 for fat loss, stubborn fat, and body-composition stacks, and FDA materials document the actual inventory: 600 mcg/mL vials, 1 mg capsules, 250 mcg rapid ODT products, and mixtures with aminophylline, glycyrrhizic acid, or N-acetyl BPC-157.
Forums and gray-market sellers extend the story to cartilage, muscle repair, and recovery. No human study supports those uses; the joint evidence is a rabbit osteoarthritis model.
Product threads lean on purity percentages and COAs. A purity number does not answer identity, salt form, impurities, aggregates, sterility, endotoxin, fill accuracy, storage, or stability after reconstitution.
Use context
Routes, doses, and cycle patterns
The studied regimen history is mostly oral daily dosing and early IV exposure. The modern market is different: subcutaneous vials, troches, ODTs, capsules, transdermal references, and combination products. Amounts, frequencies, and durations differ by source because the negative 24-week oral obesity trial says nothing about how a clinic vial is absorbed, whether a vendor ODT matches the old oral product, or which ingredient is responsible for a combination claim.
Human studies and product labels
METAOD001 single-dose IV safety study
- Purpose
- Early tolerability and exposure exploration
- Context
- Company-linked clinical summary and later LAT-8881 registry context
- Route
- Intravenous
- Amount
- 25 to 400 mcg/kg
- Frequency
- Single dose
- Duration
- Single exposure
This was safety and pharmacology work in healthy adult males, not a weight-loss efficacy regimen.
METAOD002 multi-period IV obesity study
- Purpose
- Early obesity exploration
- Context
- Company-linked clinical summary and FDA re-review
- Route
- Intravenous
- Amount
- 25, 50, and 100 mcg/kg across four single-dose periods
- Frequency
- Intermittent single-dose periods
- Duration
- About 3 weeks in the summarized source
Average weight loss was reported around 0.58 kg over 3 weeks and was not statistically different from placebo.
METAOD003 oral single-dose exploration
- Purpose
- Early oral exposure and tolerability
- Context
- Company-linked clinical summary and FDA re-review
- Route
- Oral capsule
- Amount
- 9, 27, and 54 mg
- Frequency
- Single-dose periods
- Duration
- Single-dose periods
This found no significant weight-loss difference versus placebo in the summarized source. Diarrhea at 54 mg was judged possibly related.
METAOD004 one-week oral dosing
- Purpose
- Short-term oral tolerability
- Context
- Company-linked clinical summary and LAT-8881 registry context
- Route
- Oral capsule
- Amount
- 9, 27, or 54 mg
- Frequency
- Once daily
- Duration
- 7 days
The short exposure window makes this a tolerability signal rather than evidence of fat loss. Headache, diarrhea, and flatulence were more visible at 54 mg in the summarized source.
METAOD005 12-week oral obesity study
- Purpose
- Obesity and waist-measure signal
- Context
- Abstract report and sponsor release
- Route
- Oral capsule
- Amount
- 1, 5, 10, 20, or 30 mg
- Frequency
- Once daily after placebo run-in
- Duration
- 12 weeks
The reported signal was modest, with the most visible effect around 1 mg/day. Because this comes from an abstract and sponsor-release material, weigh it below the later negative OPTIONS trial.
METAOD006 and OPTIONS 24-week oral obesity trial
- Purpose
- Obesity efficacy
- Context
- Company disclosure, ClinicalTrials.gov context, and FDA re-review
- Route
- Oral tablet
- Amount
- 0.25, 0.5, or 1 mg
- Frequency
- Once daily, with diet and exercise after placebo run-in
- Duration
- 24 weeks
The strongest human efficacy result for AOD-9604 found no statistically significant weight-loss benefit versus placebo at 12 or 24 weeks.
Real-world discussion
Clinic and community fat-loss protocols
- Purpose
- Fat loss and body-composition discussion
- Context
- Clinics, troche suppliers, and community reports
- Route
- Subcutaneous injection, with oral troches and lozenges also marketed
- Amount
- Most reports describe 250 to 300 mcg per day by injection, usually fasted in the morning. Oral troche products are commonly marketed around 500 mcg per day.
- Frequency
- Once daily in most community descriptions
- Duration
- Typically 8 to 12 week cycles
AOD-9604 failed as an obesity drug in development, so these schedules have no controlled human outcome backing. The fasted-morning timing is community lore rather than studied practice. Not verified as a regimen; context only.
What varies
- Goal: fat-loss claims sit against the negative 24-week obesity trial, not just animal lipolysis papers or clinic marketing.
- Route: oral and IV human studies leave subcutaneous absorption, transdermal delivery, troche or ODT exposure, and combination-product attribution unanswered.
- Amount: study amounts range from IV 25 to 400 mcg/kg single exposure to oral 0.25 to 30 mg/day in the longer studies and 9 to 54 mg in the single-dose and 7-day tolerability work; marketed examples include 600 mcg/mL vials, 1 mg capsules, and 250 mcg ODT products.
- Duration: study durations include single exposure, 7 days, 12 weeks, and 24 weeks; cycle lengths in market examples are often not published.
- Product form: vials, troches, ODTs, capsules, and combinations create different identity, sterility, concentration, and stability questions.
Human data
Human evidence
About six company-era human studies exist, and their main function now is to limit the claims. Early IV and short oral studies established tolerability more than efficacy. The 12-week oral obesity study reported a modest signal, most visible around 1 mg per day, but only through abstract and sponsor-release material. The 24-week OPTIONS trial, the strongest human result the molecule has, found no statistically significant weight-loss benefit versus placebo. FDA later added that it found no human data for subcutaneous or transdermal use and only limited longer-term safety information.
Evidence maturity
AOD-9604's obesity program failed its largest human trial, and today's injectable market runs on routes with no controlled human data.
Rodent studies reported fat-oxidation and body-weight signals tied to beta-3 adrenergic biology, launching an obesity drug program.
Small company-era IV and oral studies explored tolerability without producing meaningful efficacy signals.
A roughly 300-person study reported a modest low-dose signal, but only through abstract and sponsor-release material.
The roughly 500-patient randomized trial found no statistically significant weight loss versus placebo, and the obesity program was discontinued.
No approved product exists, FDA's 2024 review found no human data for marketed subcutaneous or transdermal routes, and PCAC voted 12-0 against 503A bulks listing.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| METAOD001 | 15 healthy adult males | Early single-dose clinical safety study | Investigational AOD-9604 | IV 25 to 400 mcg/kg single exposure was summarized as well tolerated, with no notable IGF-1, glucose, vital-sign, or ECG issues reported in the company-linked summary. | Small healthy-volunteer safety study; obesity, body-composition, and repair outcomes were outside this study. | weak |
| METAOD002 | 23 obese adult males | Early multi-period IV obesity exploration | Investigational AOD-9604 | IV 25, 50, and 100 mcg/kg periods were associated with about 0.58 kg average weight loss over 3 weeks, not statistically different from placebo in the summarized source. | Small, short, IV study; too limited to show clinically meaningful fat loss. | weak |
| METAOD003 and METAOD004 | Obese adult males | Oral single-dose and 7-day studies | Investigational oral AOD-9604 | Oral 9, 27, and 54 mg exposures explored tolerability and early response. The 7-day study does not provide persuasive weight-loss evidence. | Very short oral exposure and limited efficacy meaning; higher-dose GI complaints appeared in summaries. | weak |
| METAOD005 | 300 obese adults | 12-week oral obesity study after placebo run-in | Investigational oral AOD-9604 | Abstract and company-release materials reported modest weight and waist effects, with the most visible signal around 1 mg/day. | A full peer-reviewed efficacy publication was not found, so the positive signal carries less weight than a complete published randomized trial. | weak |
| METAOD006 and OPTIONS | 536 enrolled and 502 randomized obese adults | 24-week randomized oral obesity trial | Investigational oral AOD-9604 | Oral 0.25, 0.5, or 1 mg once daily with diet and exercise did not produce statistically significant weight-loss benefit versus placebo at the primary or secondary endpoints. | Negative for obesity efficacy; it is still the largest human obesity result, even though it leaves current market routes untested. | moderate |
| LAT-8881 registry history | Later pain-program registry context | ClinicalTrials.gov protocol context | LAT-8881 development history | Later protocols state that the obesity program was discontinued after efficacy failure and describe a separate pain-mechanism hypothesis. | It helps explain development history and the later mechanism hypothesis, but it is not evidence for obesity, repair, or consumer peptide benefits. | weak |
Cautions
Safety and unknowns
- FDA emphasized limited clinical safety information, no human pharmacokinetic or pharmacodynamic data for proposed subcutaneous or transdermal use, and insufficient support for long-term obesity use.
- Company-linked summaries described placebo-like tolerability across six studies, no treatment-related withdrawals, no clinically meaningful IGF-1 shifts, no significant glucose effects in measured windows, and no anti-AOD antibodies in the tested subset. Those limited study settings do not settle long-term safety or the risks of today's marketed routes.
- FDA's nonclinical review raised issues including possible negative bone effects in oral rat studies, possible liver-toxicity signals in cynomolgus monkey studies, and equivocal genotoxicity findings.
- Headache and gastrointestinal symptoms appeared in summarized human studies; severe chest tightness and mild to moderate euphoria were reported as possibly related in one summarized IV study.
- FDA's Innoveix recall involved injectable AOD-9604 3 mg product due to lack of sterility assurance, which is directly relevant to vial-market risk.
Product quality
A vial label is only a starting point
FDA found that AOD-9604 nomination materials and public COAs lacked critical characterization data, including peptide-related impurities, aggregates, microbial testing, and endotoxin testing.
FDA also described a naming inconsistency where a nomination for one bulk substance was accompanied by a COA for another salt form.
Public COAs reported high purity values and sample-specific LCMS/MS or HPLC results, but they did not answer sterile injectable quality, correct net content across lots, established stability, or representative market quality.
FDA enforcement and recall examples connect AOD-9604 products with compounding-process concerns, sterility-assurance problems, and products that did not qualify for 503A exemptions.
Identity and salt form
AOD-9604 free base, acetate forms, and naming inconsistencies can point to different materials than the buyer thinks they are comparing.
Impurities and aggregates
Peptide-related impurities and aggregates matter for immune reactions and route-specific tolerability, especially when products are injected.
Sterility and endotoxin
A purity percentage says little about sterile handling or endotoxin burden. FDA's recall and compounding records make this a concrete issue for AOD products.
Fill amount and concentration
A vial label or COA sample result is not enough by itself: every vial still has to match the advertised amount, concentration, and usable dose after reconstitution.
Storage and shipping
Peptides can degrade with poor handling. Stability after shipping, storage, and reconstitution is separate from a one-time identity or purity report.
Mechanism
How it is proposed to work
AOD-9604 was designed from a fat-metabolism region of human growth hormone. Animal studies suggested less fat storage, more fat oxidation, and beta-3 adrenergic dependence without classic full-growth-hormone receptor activity. That made the obesity program scientifically plausible, but plausible mechanism did not become convincing human weight-loss efficacy.
Foundational work described the hGH 177-191 region as antilipogenic and framed AOD-9604 as a cyclic anti-obesity peptide derived from the C-terminal domain of human growth hormone.
PubMed-indexed preclinical studies reported reduced body-weight gain in obese Zucker rats, lipid-metabolism effects, increased fat oxidation in obese mice, and loss of effect in beta-3 adrenergic receptor knockout mice.
Human studies mainly tracked indirect metabolic markers such as NEFA, glucose, insulin, oral glucose tolerance, and IGF-1. Available summaries did not report major IGF-1 elevations or obvious glucose deterioration in measured windows, but those marker results did not overcome the negative obesity outcome.
Later LAT-8881 pain-program protocols describe a different mechanism hypothesis involving LANCL1, which shows that later development moved away from the original anti-obesity program.
AOD-9604 is the C-terminal fragment of growth hormone (residues 177-191) with a tyrosine added for stability. It was designed to isolate GH's fat-metabolism effect from its growth effects: a mechanism that made sense on paper and then failed to deliver in human obesity trials.
FAQ
Common questions
Does AOD-9604 work for fat loss?
The human trials said no, which is why development stopped. It is still marketed for fat loss on the strength of its origin as a growth-hormone fragment, but the clinical program failed to show meaningful weight loss.
What do people report using?
Community protocols commonly describe 250 to 300 mcg per day by subcutaneous injection, fasted in the morning, in 8 to 12 week cycles. Oral troches are marketed around 500 mcg per day.
Why is AOD-9604 still sold if the trials failed?
Because marketing runs on the fragment's mechanism story rather than its trial results. Regulatory warnings and the failed development program rarely appear on sales pages.
Details
Technical details
Sources
References
- 1.
FDA PCAC briefing. FDA PCAC briefing document on AOD-9604, Dec 2024
FDA review of efficacy, routes, safety, and characterization.
- 2.
FDA safety-risk page. FDA page on bulk substances that may present significant safety risks
Current FDA safety-risk listing for compounding context.
- 3.
FDA PCAC vote. FDA PCAC vote summary, Dec 2024
Records the committee vote against 503A Bulks inclusion.
- 4.
FDA 503A categories. FDA 503A categories PDF, updated May 14 2026
Shows why older “Category 2” shorthand can be stale for AOD-9604.
- 5.
Tailor Made letter. Tailor Made warning letter
Shows AOD9604 in non-qualifying compounding operations.
- 6.
Promise Pharmacy 483. Promise Pharmacy Form 483
Process, supply-chain, and product-quality signal in an AOD-containing compounder.
- 7.
Innoveix recall. Innoveix recall
Sterility-assurance signal involving injectable AOD-9604.
- 8.
FDA GSRS identity. FDA GSRS / UNII record
Canonical identity, synonyms, and sequence mapping.
- 9.
LAT-8881 protocols. ClinicalTrials.gov LAT-8881 protocols
Confirms obesity history, six-study summary, and later repurposing.
- 10.
TGA scheduling. Australian TGA 2015 scheduling decision
Historical prescription and integrity-control signal.
- 11.
GRAS claim check. FDA GRAS inventory plus 2024 PCAC transcript note
FDA basis for GRAS-related claim checks.
- 12.
Stier 2013 review. Stier et al. 2013
Company-linked peer-reviewed human safety summary across six studies.
- 13.
More 2014 safety. Moré et al. 2014
Company-linked nonclinical safety, metabolism, and toxicology summary.
- 14.
Herd 12-week abstract. Herd et al. abstract as summarized by FDA
Meeting abstract and FDA re-review for the 12-week oral signal.
- 15.
Metabolic ASX release. Metabolic ASX release, Dec 2004
Public origin of the 2.8 kg versus 0.8 kg claim.
- 16.
OPTIONS failure record. OPTIONS failure record, 2007
Company disclosure and FDA re-review for the larger negative obesity result.
- 17.
Preclinical GH fragment. 1993 to 2001 preclinical papers
Mechanism and animal-efficacy literature.
- 18.
Preclinical metabolism. 1993 to 2001 preclinical papers
Mechanism and animal-efficacy literature.
- 19.
Preclinical fat oxidation. 1993 to 2001 preclinical papers
Mechanism and animal-efficacy literature.
- 20.
Preclinical beta-3 work. 1993 to 2001 preclinical papers
Mechanism and animal-efficacy literature.
- 21.
Preclinical safety paper. 1993 to 2001 preclinical papers
Mechanism and animal-efficacy literature.
- 22.
Preclinical toxicology. 1993 to 2001 preclinical papers
Mechanism and animal-efficacy literature.
- 23.
Rabbit OA paper. rabbit OA paper
Rabbit repair and cartilage study.
- 24.
Repair-claim examples. company clarification, vendors, and Reddit
Shows online claims and where they outrun the studies.
- 25.
Market route examples. company clarification, vendors, and Reddit
Shows online claims and where they outrun the studies.
- 26.
Forum claim examples. company clarification, vendors, and Reddit
Shows online claims and where they outrun the studies.
- 27.
Supplier COA example. public COAs and supplier spec
Product-quality signal showing why purity talk alone is incomplete.
- 28.
Public COA example. public COAs and supplier spec
Product-quality signal showing why purity talk alone is incomplete.
- 29.
Supplier spec example. public COAs and supplier spec
Product-quality signal showing why purity talk alone is incomplete.